ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1791

Psoriasis Onset Before Rheumatic Symptoms in Patients with Spondyloarthritis: Does It Relate to Clinical Characteristics and the Rheumatologist’s Diagnosis? Data from REGISPONSER Registry

Ignacio Gomez-Garcia1, Teresa García-Puga2, Nuria Barbarroja3, Mara ngeles Puche Larrubia4, Pilar Font5 and Clementina López Medina6, 1Rheumatology Department, Reina Sofia University Hospital. Cordoba (Spain) / University of Cordoba (Spain) / Maimonides Institute for Biomedical Research (IMIBIC). Cordoba (Spain) / Physical Medicine and Rehabilitation Department. Infanta Margarita Hospital. Cabra (Spain), Córdoba, Spain, 2University of Cordoba, Cordoba, Spain, 3University of Cordoba/IMIBIC/Reina Sofia Hospital, Cordoba, Spain, 4Hospital Universitario Reina Sofía, Córdoba, Spain, 5IMIBIC/Reina Sofia Hospital/University of Córdoba, Córdoba, Spain, 6Department of Rheumatology, Reina Sofia Hospital, IMIBIC, University of Cordoba, Cordoba, Spain/ Department of Rheumatology, University of Paris, Cochin Hospital, Paris, France

Meeting: ACR Convergence 2021

Keywords: Psoriatic arthritis, spondyloarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 9, 2021

Title: Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster IV: Clinical Aspects of PsA & Peripheral SpA (1773–1800)

Session Type: Poster Session D

Session Time: 8:30AM-10:30AM

Background/Purpose: To describe if the time of the onset of psoriasis (Pso) relative to the appearance of rheumatic symptoms in patients with spondyloarhtritis (SpA) is associated with a clinical phenotype, the rheumatologist’s diagnosis and the evolution of the disease.

Methods: This was a cross-sectional study with data extracted from the REGISPONSER (Spondyloarhritis Registry of the Spanish Rheumatology Society) registry. Patients were classified in two groups to compare the clinical characteristics, disease activity, radiographic damage, functional ability and received treatment: “Pso as first symptom” and “Pso after rheumatic symptoms”. Moreover, the rheumatologist’s diagnosis was compared between the two groups. We use chi-square test and Student t-test to compare qualitative and quantitative variables in both groups, respectively. Multivariate analysis was performed in variables with significant differences.

Results: A total of 433/2367 (18.3%) patients included in the REGISPONSER database had Pso onset data available. Patients with Pso as first symptom had less body mass index [0.90 (95% CI 0.83 – 0.96)], shorter disease duration [0.94 (95% CI 0.91 – 0.97)], less prevalence of HLA-B27 antigen [0.22 (95% CI 0.11 – 0.44)] and higher prevalence of dactylitis [2.12 (95% CI 1.01 – 4.46)] with regard to patients with Pso after rheumatic symptoms. Furthermore, a higher prevalence of Psoriatic Arthritis (PsA) diagnosis [257/329 (78.1%) vs 57/101 (56.4%); p< 0.001)] and a lower prevalence of ankylosing spondylitis (AS) diagnosis [68/329 (20.7%) vs 38/101 (37.6%); p< 0.001] were found in patients with Pso as first symptom vs. Pso after rheumatic symptoms. Indeed, axial involvement was less frequent in patients with Pso as first symptom [29/330 (8.8%) vs 20/103 (19.4%); p=0.003], while peripheral involvement was more frequent [192/330 (58.2%) vs 39/103 (37.9%; p< 0.001]. The use of DMARDs was not statistically different between the two groups.

Conclusion: The moment of appearance of psoriasis influences significantly the clinical phenotypic of spondyloarthritis. Thus, the presence of psoriasis before the rheumatic symptoms could determine a more frequent diagnosis of PsA by Rheumatologist.


Disclosures: I. Gomez-Garcia, None; T. García-Puga, None; N. Barbarroja, None; M. Puche Larrubia, None; P. Font, None; C. López Medina, None.

To cite this abstract in AMA style:

Gomez-Garcia I, García-Puga T, Barbarroja N, Puche Larrubia M, Font P, López Medina C. Psoriasis Onset Before Rheumatic Symptoms in Patients with Spondyloarthritis: Does It Relate to Clinical Characteristics and the Rheumatologist’s Diagnosis? Data from REGISPONSER Registry [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/psoriasis-onset-before-rheumatic-symptoms-in-patients-with-spondyloarthritis-does-it-relate-to-clinical-characteristics-and-the-rheumatologists-diagnosis-data-from-regisponser-registry/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/psoriasis-onset-before-rheumatic-symptoms-in-patients-with-spondyloarthritis-does-it-relate-to-clinical-characteristics-and-the-rheumatologists-diagnosis-data-from-regisponser-registry/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology